File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Long-term prospective randomised study of hepatitis B vaccines without booster dose in children
Title | Long-term prospective randomised study of hepatitis B vaccines without booster dose in children |
---|---|
Authors | |
Issue Date | 2009 |
Publisher | Hong Kong Academy of Medicine. |
Citation | The 14th Medical Research Conference (MRC 2009), Hong Kong, 10 January 2009. In Hong Kong Medical Journal, 2009, v. 15 n. S1, p. 7 How to Cite? |
Abstract | Introduction: Protective antibodies persisted up to 10 to 15 years after primary hepatitis B virus (HBV)
vaccination. Titres of antibody against HBV surface antigen (anti-HBs) decrease with time. Necessity for routine
booster dose remains controversial. Immunogenicity and efficacy of HBV vaccination without booster dose was
examined in the present study.
Methods: From 1984 to 1986, 318 Chinese children from HBV families aged 3 months to 11 years old were
randomised into one of the three HBV vaccine regimens without booster doses—group A: 2-dose recombinant;
group B: 3-dose recombinant; group C: 3-dose plasma-derived vaccines. HBV surface antigen (HBsAg) titres,
anti-HBs, and antibody against HBV core antigen (anti-HBc), were measured yearly.
Results: After 22 years, no subject was found to be HBsAg positive. Geometric mean titre (GMT) of antiHBs
of group A subjects was significantly lower than that of group B and C subjects at year 1, 5, 10, and 15.
No difference was observed in the GMTs between group B and C throughout the 22 years. At year 22, the
proportion of subjects with anti-HBs ≥10 mIU/mL (the protective level) for groups A, B and C were 35.3%, 76.5%,
and 52.4% respectively. The difference was statistically significant between groups A and B. A total of 72 subjects
had ≥1 episodes of anamnestic response with rises in anti-HBs titres after the primary vaccination during the 22
years study period. Of these, eight anamnestic responses were mounted from subjects with the preceding antiHBs
titre <10 mIU/mL. Three subjects became positive for anti-HBc.
Conclusion: Protective anti-HBs persisted up to 22 years after HBV vaccination without the use of booster dose.
The 3-dose regimens have a better long-term immunogenicity. However, the 2-dose recombinant HBV vaccine
was not inferior to 3-dose vaccines in terms of protection against chronic HBV infection. Booster doses were
not necessary, due to long-term immune memory. |
Persistent Identifier | http://hdl.handle.net/10722/62318 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.261 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | But, D | en_HK |
dc.contributor.author | Lai, CL | en_HK |
dc.contributor.author | Lim, WL | en_HK |
dc.contributor.author | Fung, JYY | en_HK |
dc.contributor.author | Wong, DKH | en_HK |
dc.contributor.author | Yuen, RMF | en_HK |
dc.date.accessioned | 2010-07-13T03:58:42Z | - |
dc.date.available | 2010-07-13T03:58:42Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | The 14th Medical Research Conference (MRC 2009), Hong Kong, 10 January 2009. In Hong Kong Medical Journal, 2009, v. 15 n. S1, p. 7 | - |
dc.identifier.issn | 1024-2708 | - |
dc.identifier.uri | http://hdl.handle.net/10722/62318 | - |
dc.description.abstract | Introduction: Protective antibodies persisted up to 10 to 15 years after primary hepatitis B virus (HBV) vaccination. Titres of antibody against HBV surface antigen (anti-HBs) decrease with time. Necessity for routine booster dose remains controversial. Immunogenicity and efficacy of HBV vaccination without booster dose was examined in the present study. Methods: From 1984 to 1986, 318 Chinese children from HBV families aged 3 months to 11 years old were randomised into one of the three HBV vaccine regimens without booster doses—group A: 2-dose recombinant; group B: 3-dose recombinant; group C: 3-dose plasma-derived vaccines. HBV surface antigen (HBsAg) titres, anti-HBs, and antibody against HBV core antigen (anti-HBc), were measured yearly. Results: After 22 years, no subject was found to be HBsAg positive. Geometric mean titre (GMT) of antiHBs of group A subjects was significantly lower than that of group B and C subjects at year 1, 5, 10, and 15. No difference was observed in the GMTs between group B and C throughout the 22 years. At year 22, the proportion of subjects with anti-HBs ≥10 mIU/mL (the protective level) for groups A, B and C were 35.3%, 76.5%, and 52.4% respectively. The difference was statistically significant between groups A and B. A total of 72 subjects had ≥1 episodes of anamnestic response with rises in anti-HBs titres after the primary vaccination during the 22 years study period. Of these, eight anamnestic responses were mounted from subjects with the preceding antiHBs titre <10 mIU/mL. Three subjects became positive for anti-HBc. Conclusion: Protective anti-HBs persisted up to 22 years after HBV vaccination without the use of booster dose. The 3-dose regimens have a better long-term immunogenicity. However, the 2-dose recombinant HBV vaccine was not inferior to 3-dose vaccines in terms of protection against chronic HBV infection. Booster doses were not necessary, due to long-term immune memory. | - |
dc.language | eng | en_HK |
dc.publisher | Hong Kong Academy of Medicine. | - |
dc.relation.ispartof | Hong Kong Medical Journal | - |
dc.title | Long-term prospective randomised study of hepatitis B vaccines without booster dose in children | en_HK |
dc.type | Conference_Paper | en_HK |
dc.identifier.email | Lai, CL: hrmelcl@hku.hk | en_HK |
dc.identifier.email | Fung, JYY: jfung@sicklehut.com | en_HK |
dc.identifier.email | Wong, DKH: danywong@hku.hk | en_HK |
dc.identifier.email | Yuen, RMF: mfyuen@hkucc.hku.hk | en_HK |
dc.identifier.authority | Lai, CL=rp00314 | en_HK |
dc.identifier.authority | Fung, JYY=rp00518 | en_HK |
dc.identifier.authority | Wong, DKH=rp00492 | en_HK |
dc.identifier.authority | Yuen, RMF=rp00479 | en_HK |
dc.identifier.hkuros | 158490 | en_HK |
dc.identifier.volume | 15 | - |
dc.identifier.issue | suppl. 1 | - |
dc.identifier.spage | 7 | - |
dc.identifier.epage | 7 | - |
dc.identifier.issnl | 1024-2708 | - |